CA2144319A1 - Polypeptides ctla4 recombinants et methodes d'obtention - Google Patents
Polypeptides ctla4 recombinants et methodes d'obtentionInfo
- Publication number
- CA2144319A1 CA2144319A1 CA002144319A CA2144319A CA2144319A1 CA 2144319 A1 CA2144319 A1 CA 2144319A1 CA 002144319 A CA002144319 A CA 002144319A CA 2144319 A CA2144319 A CA 2144319A CA 2144319 A1 CA2144319 A1 CA 2144319A1
- Authority
- CA
- Canada
- Prior art keywords
- ctla4
- polypeptide
- active
- protein
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La présente invention porte sur des polypeptides CTLA4 produits par recombinaison et conservant une activité de liaison B7, sans pour autant résulter de la fusion entre le CTLA4 et les gènes Ig humains. Les polypeptides CTLA4 de la présente invention comportent généralement une séquence d'acide aminé correspondant au domaine extra-cellulaire de la protéine réceptrice du CTLA4. En outre, l'invention concerne des dérivés fonctionnels des polypeptides CTLA4, y compris des mutéines et des conjugués contenant du polyéthylène glycol. L'invention porte également sur la préparation des polypeptides CTLA4 recombinants et sur les procédés de séparation des formes monomères et dimères des polypeptides recombinants ainsi que les formes des dimères actives et moins actives.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9053393A | 1993-07-09 | 1993-07-09 | |
US08/090,533 | 1993-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2144319A1 true CA2144319A1 (fr) | 1995-01-19 |
Family
ID=22223206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002144319A Abandoned CA2144319A1 (fr) | 1993-07-09 | 1994-07-08 | Polypeptides ctla4 recombinants et methodes d'obtention |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0665852A1 (fr) |
JP (1) | JPH08506247A (fr) |
AU (1) | AU7326594A (fr) |
CA (1) | CA2144319A1 (fr) |
WO (1) | WO1995001994A1 (fr) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811097A (en) * | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) * | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
EP0947582A1 (fr) * | 1998-03-31 | 1999-10-06 | Innogenetics N.V. | Une structure polypeptidique utilisable comme un squelette |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
ES2340745T3 (es) | 1998-12-23 | 2010-06-08 | Pfizer Inc. | Anticuerpos monoclonales humanos contra ctla-4. |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
EP1212422B1 (fr) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Anticorps contre l'antigene ctla-4 humain et utilisation |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
NZ536420A (en) | 2002-04-12 | 2008-04-30 | Medarex Inc | Methods of treatment using CTLA-4 antibodies |
WO2004076479A2 (fr) * | 2003-02-27 | 2004-09-10 | Theravision Gmbh | Polypeptides et procedes de fabrication associes |
EP1954311A4 (fr) | 2005-12-07 | 2009-12-23 | Medarex Inc | Régimes d'escalade de dose d'anticorps ctla-4 |
WO2007100098A1 (fr) * | 2006-03-03 | 2007-09-07 | Kyoto University | Multimere de domaine extracellulaire d'une molecule fonctionnelle de surface cellulaire |
GB0620934D0 (en) * | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
US8742079B2 (en) | 2007-08-20 | 2014-06-03 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
WO2010040105A2 (fr) | 2008-10-02 | 2010-04-08 | Trubion Pharmaceuticals, Inc. | Protéines de liaison multicibles antagonistes de cd86 |
US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
WO2011107992A2 (fr) * | 2010-03-02 | 2011-09-09 | Protalix Ltd. | Formes multimères de protéines thérapeutiques et leurs applications |
DK2665814T3 (en) | 2011-01-20 | 2017-09-11 | Protalix Ltd | NUCLEIC ACID CONSTRUCTION FOR EXPRESSION OF ALPHA-GALACTOSIDASE IN PLANTS AND PLANT CELLS |
PL3291679T3 (pl) | 2015-05-06 | 2022-04-25 | Snipr Technologies Limited | Zmiana populacji drobnoustrojowych i modyfikowanie mikrobioty |
WO2017079202A1 (fr) | 2015-11-02 | 2017-05-11 | Board Of Regents, The University Of Texas System | Méthodes d'activation de cd40 et blocage de points de contrôle immunitaires |
WO2017079746A2 (fr) | 2015-11-07 | 2017-05-11 | Multivir Inc. | Méthodes et compositions comprenant une thérapie génique suppressive de tumeur et le blocage du point de contrôle immunitaire pour le traitement du cancer |
WO2017173091A1 (fr) | 2016-03-30 | 2017-10-05 | Musc Foundation For Research Development | Méthodes pour le traitement et le diagnostic du cancer par le ciblage d'une protéine à prédominance de répétitions de glycoprotéine a (garp) et la mise en œuvre d'une immunothérapie efficace seule ou en association |
JP7131773B2 (ja) | 2016-04-29 | 2022-09-06 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | ホルモン受容体に関連する転写活性の標的尺度 |
GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
JP2020500151A (ja) | 2016-09-27 | 2020-01-09 | ボード オブ リージェンツ, ザ ユニヴァーシティー オブ テキサス システム | マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法 |
RU2755903C2 (ru) | 2016-10-12 | 2021-09-22 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Способы и композиции для tusc2-иммунотерапии |
CA3043356A1 (fr) | 2016-11-09 | 2018-05-17 | Musc Foundation For Research Development | Axe metabolique regule cd38-nad+ en immunotherapie antitumorale |
WO2018111902A1 (fr) | 2016-12-12 | 2018-06-21 | Multivir Inc. | Méthodes et compositions comprenant une thérapie génique virale et un inhibiteur de point de contrôle immunitaire pour le traitement et la prévention du cancer et des maladies infectieuses |
WO2018156973A1 (fr) | 2017-02-24 | 2018-08-30 | Board Of Regents, The University Of Texas System | Dosage pour la détection du cancer du pancréas à un stade précoce |
EP3768698A4 (fr) | 2018-03-19 | 2022-03-30 | MultiVir Inc. | Procédés et compositions comprenant une thérapie génique suppressive de tumeur et des agonistes de cd122/cd132 pour le traitement du cancer |
US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
BR112020019418A2 (pt) | 2018-03-25 | 2021-02-17 | Snipr Biome Aps. | tratamento e prevenção de infecções microbianas |
EP3773551A4 (fr) | 2018-03-27 | 2022-03-23 | Board of Regents, The University of Texas System | Composés ayant une activité antitumorale contre des cellules cancéreuses portant des mutations her2 exon 19 |
US20220033848A1 (en) | 2018-11-19 | 2022-02-03 | Board Of Regents, The University Of Texas System | A modular, polycistronic vector for car and tcr transduction |
WO2020113029A2 (fr) | 2018-11-28 | 2020-06-04 | Board Of Regents, The University Of Texas System | Édition de génome multiplex de cellules immunitaires pour améliorer la fonctionnalité et la résistance à un environnement de suppression |
BR112021010248A2 (pt) | 2018-11-29 | 2021-08-17 | Board Of Regents, The University Of Texas System | métodos para expansão ex vivo de células naturais killer e uso dos mesmos |
CA3138348A1 (fr) | 2019-05-09 | 2020-11-12 | FUJIFILM Cellular Dynamics, Inc. | Procedes de production d'hepatocytes |
TW202110431A (zh) | 2019-05-17 | 2021-03-16 | 美商癌症預防製藥股份有限公司 | 治療家族性腺瘤性瘜肉症之方法 |
US20220380765A1 (en) | 2019-11-02 | 2022-12-01 | Board Of Regents, The University Of Texas System | Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer |
WO2021113644A1 (fr) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinaisons comprenant un activateur de lymphocytes t cd8+, un inhibiteur de point de contrôle immunitaire et une radiothérapie en vue d'obtenir des effets ciblés et abscopal pour le traitement du cancer |
KR20220124718A (ko) | 2020-01-07 | 2022-09-14 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 암 치료를 위한 개선된 인간 메틸 티오아데노신/아데노신 고갈 효소 변이체 |
EP4107173A1 (fr) | 2020-02-17 | 2022-12-28 | Board of Regents, The University of Texas System | Procédés d'expansion de lymphocytes infiltrant les tumeurs et leur utilisation |
EP4153301A2 (fr) | 2020-05-21 | 2023-03-29 | Board of Regents, The University of Texas System | Récepteurs de lymphocytes t ayant une spécificité pour le vgll1 et leurs utilisations |
WO2021247836A1 (fr) | 2020-06-03 | 2021-12-09 | Board Of Regents, The University Of Texas System | Méthodes de ciblage de shp-2 pour surmonter une résistance |
WO2022104109A1 (fr) | 2020-11-13 | 2022-05-19 | Catamaran Bio, Inc. | Cellules tueuses naturelles génétiquement modifiées et procédés d'utilisation associés |
US20220162288A1 (en) | 2020-11-25 | 2022-05-26 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
CN117529338A (zh) | 2021-01-19 | 2024-02-06 | 威廉马歇莱思大学 | 多肽的骨特异性递送 |
CA3234457A1 (fr) | 2021-10-05 | 2023-04-13 | Cytovia Therapeutics, Llc | Cellules tueuses naturelles et leurs methodes d'utilisation |
WO2023068382A2 (fr) | 2021-10-20 | 2023-04-27 | Takeda Pharmaceutical Company Limited | Compositions ciblant bcma et leurs procédés d'utilisation |
WO2023076880A1 (fr) | 2021-10-25 | 2023-05-04 | Board Of Regents, The University Of Texas System | Thérapie ciblant le foxo1 pour le traitement du cancer |
WO2023211972A1 (fr) | 2022-04-28 | 2023-11-02 | Medical University Of South Carolina | Lymphocytes t régulateurs modifiés par un récepteur antigénique chimérique pour le traitement du cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5770197A (en) * | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
DE122007000078I2 (de) * | 1991-06-27 | 2011-01-13 | Bristol Myers Squibb Co | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
-
1994
- 1994-07-08 CA CA002144319A patent/CA2144319A1/fr not_active Abandoned
- 1994-07-08 EP EP94923387A patent/EP0665852A1/fr not_active Withdrawn
- 1994-07-08 JP JP7504186A patent/JPH08506247A/ja active Pending
- 1994-07-08 AU AU73265/94A patent/AU7326594A/en not_active Abandoned
- 1994-07-08 WO PCT/US1994/007685 patent/WO1995001994A1/fr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JPH08506247A (ja) | 1996-07-09 |
EP0665852A1 (fr) | 1995-08-09 |
AU7326594A (en) | 1995-02-06 |
WO1995001994A1 (fr) | 1995-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2144319A1 (fr) | Polypeptides ctla4 recombinants et methodes d'obtention | |
KR100376544B1 (ko) | 티(t)세포조절물질및방법 | |
AU755941B2 (en) | Soluble MHC complexes and methods of use thereof | |
US5623053A (en) | Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5 | |
JP3808553B2 (ja) | Ctla4変異体分子およびそれの使用 | |
WO2017076308A1 (fr) | Tcr pour identifier un oligopeptide d'antigènes ny-eso-1 | |
US20100136032A1 (en) | Trimeric ox40-immunoglobulin fusion protein and methods of use | |
JPH10503371A (ja) | 新規化合物 | |
DE102006041455B4 (de) | Verfahren zur Herstellung einer einen stabilisierten funktionellen humanen Einzelketten-Antigen-erkennenden-TCR (scTCR) exprimierenden Zelllinie, damit hergestellt Zelllinie, stabilisierter TAA-spezifischer scTCR, deren Verwendungen und diese enthaltende pharmazeutische Zusammmensetzungen | |
CA2123894A1 (fr) | Anticorps heterodimeriques bispecifiques | |
JP2005514006A (ja) | 物質 | |
WO2007085084A1 (fr) | Protéines hybrides epo-fc humaines recombinées présentant une demi-vie prolongée et une activité érythropoïétique accrue in vivo | |
US8158767B2 (en) | Polypeptides and methods for making the same | |
CA2251819A1 (fr) | Produit et procede nouveaux pour molecules veto des lymphocytes t | |
AU2011265482B2 (en) | Trimeric OX40L-immunoglobulin fusion protein and methods of use | |
KR0172969B1 (ko) | 인터페론 알파 및 베타에 대해 높은 친화력을 갖는 수용성 폴리펩티드 | |
US5525708A (en) | Covalent dimer of kit ligand | |
AU2013263717B2 (en) | Trimeric OX40L-immunoglobulin fusion protein and methods of use | |
Cox et al. | Refolding and characterization of recombinant human soluble CTLA-4 expressed in Escherichia coli | |
KR100260272B1 (ko) | Tpo활성을 갖는 단백질의 아미노산을 코딩하는 염기 서열을 포함하는 dna | |
CA2416794A1 (fr) | Methode et composition de modification d'une pathologie a mediation assuree par les lymphocytes t | |
WO2022262835A1 (fr) | Tcr pour identifier un antigène afp et séquence codant pour celui-ci | |
WO2022166904A1 (fr) | Récepteur de lymphocytes t pour identifier l'hpv | |
JPH11509723A (ja) | 抗原特異的グリコシル化阻害因子の製法 | |
AU2004202633B2 (en) | Antibodies and immunoglobulin fusion proteins having modified effector functions and uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |